1 Dopaminergic-related Anatomical Pattern of Dorsal Striatum in Schizophrenia

- 2 Chao Xie^{1,2}, Shitong Xiang^{1,2}, Yueyuan Zheng³, Chun Shen^{1,2}, Xuerui Peng⁴, Yuzhu Li^{1,2}, Wei Cheng^{1,2}, Xiao
- 3 Chang^{1,2}, Jingliang Cheng⁵, Long-Biao Cui⁶, Chu-Chung Huang^{7,8}, Nanyu Kuang^{1,2}, Chunbo Li⁹, Ching-Po
- 4 Lin¹⁰, Cheng Luo^{11,12,13}, Yingying Tang⁹, Jijun Wang⁹, Xinran Wu^{1,2}, Dezhong Yao^{11,12,13}, Jie Zhang^{1,2},
- 5 Tianhong Zhang⁹, Andreas Heinz¹⁴, Trevor W. Robbins^{1,15}, Oliver D. Howes^{16,17,18}, Gunter Schumann^{1,19,20,21},
- 6 Tianye Jia 1,2,22 , Jianfeng Feng 1,2,23,24,25,26,27
- 7
- 8 ¹Institute of Science and Technology for Brain-Inspired Intelligence, Fudan University, Shanghai, China
- 9 ²Key Laboratory of Computational Neuroscience and Brain-Inspired Intelligence (Fudan University), Ministry
- 10 of Education, China
- ³Department of Psychology, University of Hong Kong, Hong Kong, China
- ⁴Faculty of Psychology, Chair of Lifespan Developmental Neuroscience, Technische Universität Dresden,
- 13 Dresden, Germany
- ⁵Department of MRI, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
- ⁶Department of Clinical Psychology, Fourth Military Medical University, Xian, China
- ⁷Shanghai Key Laboratory of Brain Functional Genomics (Ministry of Education), Affiliated Mental Health
- 17 Center (ECNU), School of Psychology and Cognitive Science, East China Normal University, Shanghai,18 China
- ⁸Shanghai Changing Mental Health Center, Shanghai, PR China. 15Department of Psychiatry, Taipei Veterans
- 20 General Hospital, Taipei, Taiwan
- ⁹Shanghai Key Laboratory of Psychotic Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong
- 22 University School of Medicine, Shanghai, China
- ²³¹⁰Institute of Neuroscience, National Yang Ming Chiao Tung University, Taipei, Taiwan
- ²⁴ ¹¹The Clinical Hospital of Chengdu Brain Science Institute, MOE Key Lab for Neuroinformation, School of
- 25 Life Science and Technology, University of Electronic Science and Technology of China, Chengdu, China
- ¹²High-Field Magnetic Resonance Brain Imaging Key Laboratory of Sichuan Province, Center for Information
- 27 in Medicine, University of Electronic Science and Technology of China, Chengdu, China
- ¹³Research Unit of NeuroInformation (2019RU035), Chinese Academy of Medical Sciences, Chengdu, China
- ¹⁴Department of Psychiatry and Psychotherapy, Charité–Universitätsmedizin Berlin, corporate member of
- 30 Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
- 31 ¹⁵University of Cambridge, Cambridge, UK
- ¹⁶Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK
- 33 ¹⁷Institute of Clinical Sciences, Faculty of Medicine, Imperial College London, London, UK
- 34 ¹⁸South London and Maudsley NHS Foundation Trust, London, UK
- ¹⁹PONS-Research Group, Charité Mental Health, Department of Psychiatry and Psychotherapy, Campus
- 36 Charité Mitte, Berlin, Germany
- ²⁰Department of Sports and Health Sciences, University of Potsdam, Potsdam, Germany.
- 38 ²¹PONS Centre, Institute for Science and Technology of Brain-inspired Intelligence (ISTBI), Fudan University,

- 39 Shanghai, China
- 40 ²²SGDP Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London SE5
- 41 8AF, UK
- 42 ²³Fudan ISTBI-ZJNU Algorithm Centre for Brain-Inspired Intelligence, Zhejiang Normal University, Jinhua,
- 43 China
- 44 ²⁴MOE Frontiers Center for Brain Science, Fudan University, Shanghai, China
- 45 ²⁵Zhangjiang Fudan International Innovation Center, Shanghai, China
- 46 ²⁶School of Data Science, Fudan University, Shanghai, China
- 47 ²⁷Department of Computer Science, University of Warwick, Coventry, UK
- 48
- 49 *Correspondece: tianyejia@fudan.edu.cn; jianfeng64@gmail.com
- 50 Drs. Tianye Jia, Oliver D. Howes, Gunter Schumann and Jianfeng Feng contributed equally to this work
- 51

52 Abstract

53 Striatal dopaminergic overactivity was hypothesized as the core pathophysiology of schizophrenia. 54 However, morphological alterations of striatum in schizophrenia remains exclusive, largely because brain 55 regional heterogeneity limited traditional group-mean based approach. Leveraging third-party brain maps of 56 neurotransmitter and cognition behaviours, we developed a pattern-based representation feature score (ReFS) 57 to investigate structural spatial pattern variation in schizophrenia. Structural ReFS of subcortical regions, 58 particularly the striatum, were linked to schizophrenia diagnosis, symptom severity, and genetic susceptibility. 59 Dopaminergic-ReFS of striatum was increased in schizophrenia patients and reliably reproduced across 13 60 datasets. The pattern-based ReFS effectively captured the shared genetic pathways underlying both 61 schizophrenia and striatum. The results provide convergent, multimodal suggest the central role of striatal 62 spatial patterns in schizophrenia psychopathologies and and open new avenues to develop individualized 63 treatments for psychotic disorders.

64 Introduction

65 Schizophrenia and related psychotic disorders are major contributors to worldwide disease burden, which is 66 partly due to the lack of efficacy of antipsychotic drugs for many patients, as well as significant side effects caused 67 by the medication (1). Both shortcomings are likely related to an insufficient understanding of the neurobiological 68 mechanisms underlying the disorder. Thus there is a need to improve understanding of the pathophysiology of 69 schizophrenia to help develop better treatments (2). Several lines of in vivo imaging evidence suggest that 70 increased striatal dopamine synthesis and release capacity underlie psychotic symptoms (3), including across 71 disorders (4). While these studies identify the striatum as a key brain region in the etiology of psychotic disorders, a 72 comprehensive understanding of striatal abnormalities beyond increased dopamine release remains elusive (5). In 73 particular, the evidence for striatal volume alterations in schizophrenia is inconsistent (6, 7).

74 One reason for this inconsistency could be because group mean-based gray matter volume of brain regions has 75 commonly been used to examine the structural differences in schizophrenia, based on the implicit assumption that 76 there is homogeneity in the measure between groups within each region of interest. However, mounting evidence 77 suggests there is greater heterogeneity among structural measures in schizophrenia patients compared to controls 78 (8). Moreover, other evidence shows that levels and activity of neurotransmitter systems varied spatial distribution 79 within brain regions, and that people with schizophrenia show differences in this which are missed by regional 80 comparisons (9, 10). These findings indicate that the region-based approaches to analysis brain data miss intricate, 81 high-dimensional spatial information within the brain that are relevant to understanding mental disorders such as

82 schizophrenia(11, 12).

83 To address this, we aimed to develop and test a reference-based method that analysed the pattern of variation 84 in brain structural data (Fig S1). We decomposed the complex spatial information of brain structure in MRI scans 85 by transforming region-level spatial pattern of grey matter volume into a multidimensional representational space 86 that was constructed using a specific third-party functional reference map (Fig. 1a). Specifically, for each brain 87 region, we normalized individual-level grey matter volume (GMV) and group-level functional reference maps, 88 followed by calculating the paired-wise spatial similarity for each individual. This process generates 89 representational feature scores (ReFS) of latent brain functions for each brain region. We then tested and 90 demonstrated that the spatial reference was highly reliable across datasets, and the structural ReFS has excellent 91 reproducibility across scanner types, sequences, and time points, as well as a high sensitivity to individual 92 differences (Table S1, Fig. 1b and Fig S3-6). Next, we discovered that structural ReFS of subcortical regions, 93 particularly the striatum, were linked to schizophrenia diagnosis, symptom severity, and genetic susceptibility (Fig 94 S2). Finally, we revealed that it was the reference-based ReFS, rather than mean-based volume based on region of 95 interest analysis, that effectively captured the shared genetic pathways underlying both schizophrenia and brain 96 structure.

97

98 Results

99 Altered representation feature scores (ReFS) of striatum structure in schizophrenia.

100 As neurotransmitter receptors are central to the propagation of signals in the human brain, we first estimated 101 brain structural representational feature scores based on neurotransmitter maps derived from positron emission 102 tomography (termed as PET-ReFS, Fig S7). We found that in a large-scale multisite schizophrenia dataset (1,229 103 SCZ participants, 1,237 HC participants, Table S2), the Schizophrenia group showed significantly higher 104 dopamine-ReFS of striatal regions, including posterior putamen (pPUT), anterior putamen (aPUT) and core 105 Nucleus Accumbens (coreNAC) (Fig. 1c, Table S3). Besides, we also found that schizophrenia patients showed 106 lower gamma-aminobutyric acid (GABAa)-ReFS in aPUT and pPUT (Fig. 1c, Table S3). After statistically 107 accounting for the influence of one another, the results of GABAa-ReFS and dopamine-ReFS remained significant 108 (**Table S3**), suggesting that the two neurotransmitters have unique contributions to the neurobiological mechanisms 109 of schizophrenia.

110 Whereas in the striatum we found differences in ReFS, but not in mean-based GMV, significant group 111 differences in regional mean and variance of grey matter volume (GMV) were apparent in non-striatal regions (**Fig.**

112 **1c and Table S3**), especially the hippocampus (HIP) and thalamus (THA), which is consistent with previous mean-

based GMV studies (6, 13). We further revealed that subcortical regions with higher dopamine synthesis capacity

114 (F-DOPA) demonstrated less differentiated mean-based GMV ($\tau = -0.58$, P < 0.001, Fig. 1d) but higher F-FOPA-

115 ReFS abnormalities ($\tau = 0.48$, P < 0.001, Fig. 1e) between schizophrenic patients and controls. The results suggest

116 that the reference-based spatial pattern was more closer to schizophrenia etiology.

117 Moreover, with a dataset consisting of healthy controls, schizophrenia patients, and unaffected siblings, we 118 observed that the PET-ReFS revealed greater group differences than for mean-based GMV, especially in the 119 striatum (t = 2.37, P = 0.019, Fig. 1f) and the mean-based GMV of subcortical regions revealed no significant 120 group differences (Fig. 1f, Table S4). For example, F-DOPA-ReFS in pPUT showed an apparent genetic 121 susceptibility gradient for schizophrenia ($F_{(2,72)} = 10.64$, P = 8.92E-05) (Fig. 1g and Table S4), which is consistent 122 with previous finding that elevated dopamine synthesis capacity (F-DOPA update) in the dorsal striatum of subjects 123 at ultra-high risk for psychosis (14). These results suggest that the pattern-based representational analysis is 124 sensitive in detecting the morphological disruptions associated with dopaminergic alterations in schizophrenia, and 125 structural ReFS serve as an intermediate structural phenotype linking brain structure and genetic mechanisms 126 underlying schizophrenia.

Furthermore, the PET-ReFS showed consistent group differences across all 13 datasets (**Table S5**), as shown in Figure 1 (pPUT: Cohen's $d 0.30 \sim 0.99$; Overall: t = 10.62, Cohen's d = 0.49, P = 8.17E-26; **Fig1. h**). Subsequent sensitivity analyses showed that the effect of F-DOPA-ReFS in pPUT was robust to clinical subgroups (first episode and chronic, **Fig1. h**), disease duration (long and short duration groups), sex (male and female groups), and age (young and old groups) (**Table S6**), while the effect of GABAa-ReFS in pPUT was observed in the chronic patients, but not in the first-episodic subgroup (**Fig1. h** and **Table S6**).

In summary, these findings indicated that reference-based spatial pattern analysis exhibits high consistency and sensitivity, and it outperforms traditional univariate mean-based analysis in detecting fine-grained structural abnormalities within dopaminergic brain regions.

136 Structural abnormality of dorsal striatal ReFS with latent cognitive factor in schizophrenia

Databases of brain activation maps provides a quantitative approach to infer plausible cognitive processes related to a spatial pattern, which might provide greater insight into the nature of the mental processes that are disrupted in the course of schizophrenia (*15*). We utilized meta-analytical decoding references from the *Neurosynth* dataset to transform individual-level spatial pattern of each subcortical region into a high-dimensional latent

141 cognitive factor (termed as Cog-ReFS, Fig S8) (16, 17). Again, after controlling for multiple comparisons with the 142 Benjamini–Hochberg procedure (16 region*539 cognitive factors), we found that the abnormalities of Cog-ReFS in 143 schizophrenia patients were mainly located in dorsal striatal regions (63.4%, 1009/1591 significant Cog-ReFS), 144 especially the posterior globus pallidus (pGP, 247 Cog-ReFS) and pPUT (274 Cog-ReFS) (Fig. 2 a and Table S7). 145 For instance, we observed significantly increased Cog-ReFS in pPUT with sensory-motor factors, such as "eye 146 movement" and "hand", as well as social factors and decisions, such as "theory of mind" and "appraisal" in 147 schizophrenia patients (Fig. 2b). Such an observation is in line with characteristic deficits or deteriorations in both 148 motor and social factors of schizophrenia (18). Similarly, schizophrenia patients also showed a greater Cog-ReFS 149 of motor-related factors (such as "finger tapping") but a lower Cog-ReFS for emotional and social functions such as 150 "familiarity" and "fearful face" in pGP (Fig. 2b), where the "finger tapping" test is a commonly adopted measure 151 of motor deficits in schizophrenia (19). In addition, for Cog-ReFS in the dorsal anterior thalamus (daTHA), the 152 "illusion" term was the most prominent finding (Fig. 2b). Notably, delusions-related functions ("biases", 153 "appraisal") are the hallmark positive symptoms of schizophrenia (20, 21).

Further, by investigating the correlations between the Cog-ReFS case/control differences and the third-party pattern similarity of cognitive factor maps and neurotransmitter maps (**Supplementary method and Fig S9**), we confirmed that the contribution of Cog-ReFS for schizophrenia could be partly explained by the neurotransmitters (**Fig. 2c, Table S8**). The above results altogether hence suggested that structural representational pattern could integrate cognitive factor and molecular neurotransmitter to delineate the neuropsychopathological mechanism of schizophrenia convergently.

160 We then investigated whether the high-dimensional Cog-ReFS in subcortical brain regions could predict the 161 clinical characterisation of schizophrenia, as measured by the Positive and Negative Syndrome Scale (PANSS). 162 Leveraging a modified linear predictive model (Supplementary Methods and Fig S10), we found that subcortical 163 Cog-ReFS could significantly predict the summary symptom score and all three symptom subscales (Summary 164 score: r = 0.10, P = 8.42E-05; Positive symptoms: r = 0.075, P = 0.011; Negative symptoms: r = 0.13, P = 5.37E-0.012165 05; General symptoms: r = 0.12, P = 1.47E-04, Fig. 2d). We also found that the predictive weight of positive and 166 negative subscale show significantly lower similarity (Fig. 2e, Table S9), suggesting that the latent cognitive 167 factors mapping could effectively characterise the different neurobiological configurations of positive and negative 168 schizophrenia symptoms. In terms of the regional predictive weights, the dorsal striatal regions again show 169 predominant contributions, especially the GP and PUT (Fig. 2f, Table S9). At last, we show that only in aGP and 170 pPUT, the positive and negative predictors of schizophrenia symptoms were significantly associated with the Cog-

171 ReFS case/control differences (Table S7-c, Fig. 2g and Fig S11, Table S9). These results might indicate that the
172 psychopathology of schizophrenia and the clinical symptoms of schizophrenia patients could share similar
173 cognitive abnormality spectra centred at the dorsal striatum.

174 Genetic links between structural ReFS and schizophrenia

Despite high heritability of both schizophrenia and striatal mean-based volumes, they were reported not to share similar genetic architectures(22). Given the above higher clinical relevance of reference-based spatial pattern for SCZ than mean-based volume, we last investigated whether structural ReFS with higher information specificity might help to bridge the gap between structural brain genetics and risk for schizophnreia.

179 Utilised imaging-genetic data of 34,497 participants of British ancestry from UK Biobank, we found the mean 180 heritability (h^2) of brain Cog-ReFS (8624, 16 regions* 539 cognitive factors) across the 16 subcortical regions as 181 30.1% (7.7%~61.9%, all P<0.001, Table S10 and Fig S12). While the above heritability levels of Cog-ReFS are 182 comparable with previous brain structural findings (23, 24), they are largely unchanged after regressing the 183 corresponding brain volume (mean $h^2 = 28.6\%$, Difference heritability = 1.5%; individual heritability changes vary 184 from -1.1% for vaTHA to 4.39% for aGP) (Table S11 and Fig S12). Hence, the subcortical Cog-ReFS may help to 185 capture the remaining genetic variance of the subcortical structure that was largely missed by using volumetric 186 measurements alone.

We then used a high-definition likelihood method to estimate the genetic correlation between schizophrenia and subcortical Cog-ReFS (*22, 25*) (**Fig. 3a left**). After controlling for multiple comparisons, the Cog-ReFS of all 16 subcortical regions had significant genetic correlations with schizophrenia (|Rg|: 0.022~ 0.153, 2676 out of 8624 ReFS, Fig. 3b, **Fig. 3a right** and **Table S12**). Remarkably, using the Cog-ReFS of pPUT, we identified 116 risk Cog-terms (Rg 0.037~0.089, mainly for sensorimotor and attentional factors) and 122 protective Cog-terms (Rg -0.118~-0.033, mainly for social and language factors) for schizophrenia (**Fig. 3b** and **Table S13**).

We also identified significant genetic correlations between the PET-ReFS of pPUT with schizophrenia, i.e. positive for the ReFS of D2 (dopamine D2), F-DOPA and DAT (dopamine transporter) and negative for the ReFS of SERT (serotonin transporter) and GABAa (**Fig. 3b** and **Table S14**). In contrast, the genetic correlation between volumetric pPUT and SCZ was not significant (Rg = -0.01, P = 0.46), consistent with previous studies (26) (**Fig. 3b** and **Table S15**). Further, also in pPUT, the magnitude of genetic correlations between Cog-ReFS and schizophrenia was significantly associated with the Cog-ReFS difference between schizophrenia patients and controls (r = 0.84, P perm = 0.01, Fig S14), hence reassuring the central role of dorsal striatum for the shared cognitive abnormalities of

200 the psychopathology of schizophrenia and the clinical symptoms of schizophrenia.

201 Finally, we investigated univariate genetic variants shared between schizophrenia and subcortical Cog-ReFS. 202 By associating subcortical ReFS (8624, 539*16) with 279 single nucleotide polymorphisms (SNPs) identified in a 203 recent schizophrenia genome-wide association study (GWAS) (26), we found significant SNP-brain associations for 204 172 out of 279 SNPs (70%) after correction for multiple testing (Fig. 3c), with four top SNPs represented 46% of 205 all significant SNP-brain associations (Fig. 3c and Table S16). In contrast, the subcortical volumes only have 206 significant associations with 37 out of 279 SNPs (13%, Table S17). The associations of the four top SNPs showed 207 different regional distributions (Fig. 3d, Table S18). For instance, the T allele of rs13107325 had the greatest 208 number of associations across all the 16 subcortical regions and was also one of the top risk genetic effects in the 209 original schizophrenia GWAS (OR = 1.15, P = 2.99E-23) (26). The rs13107325 was associated with increased Cog-210 ReFS in pPUT for motor-related factors and "illusion" and also decreased Cog-ReFS in pPUT with "feelings", 211 "language", and "theory of mind" (Fig. 3e and Table S15). The above results hence confirmed highly overlapped 212 genetic substrates between schizophrenia and subcortical brain regions using our ReFS approach.

213 Discussion

214 The present study demonstrated the crucial role of dopamine-based striatal representational feature score 215 (ReFS) in schizophrenic psychopathology, and remarkably, the increased striatal dopamine-ReFS in schizophrenic 216 patients could be consistently reproduced across all 13 tested independent datasets. In contrast, previous large-217 sample structural studies rarely found consistent mean/variance-based volumetric alternations of striatum in chronic 218 or antipsychotic-free schizophrenia patients (27, 28). Such a discrepancy could be explained by our observations 219 that brain regions with higher dopamine density tend to have diminished case-control brain mean-based volume 220 difference while, instead, showing increased differences in the corresponding dopamine-ReFS. Notably, this effect 221 of increased striatal dopamine-ReFS was also evident in the antipsychotic-free schizophrenia subgroup and the 222 first-degree healthy relatives of schizophrenia patients. Therefore, the increased striatal dopamine-ReFS were most 223 unlikely the results of confounding effects from antipsychotic medications and could serve as endophenotypic 224 biomarkers for the vulnerability of dopaminergic dysfunction in schizophrenia.

Further, with high-dimensional latent cognitive factors, we found that the structural Cog-ReFS abnormalities in schizophrenia were also primarily located in the striatum, particularly the dorsal part (i.e. the globus pallidus, GP and the putamen, PUT), which corroborates a recent proposition asserting the central role of the dorsal striatum in the pathophysiology of schizophrenia (29). The dorsal striatum has been proposed as an integrative hub that regulates information transactions between limbic and motor regions (*30*), most notably through the dopaminergic

230 projections from SNc. Our results indicated that Cog-ReFS abnormalities of the dorsal striatum in schizophrenia 231 could influence multiple latent cognitive domains (i.e., motor-related, decision-making, and social-emotional functions). Besides, in the predictive model for the three schizophrenia symptom subscales (i.e., positive, negative 232 233 and general subscales from PANSS) using all subcortical Cog-ReFS, the dorsal striatum was the primary 234 contributor. These findings supported that dorsal striatum dysfunction was not merely associated with motor 235 deficits in schizophrenia but may also contribute to other psychopathologies (such as emotionlessness and delusion) 236 in schizophrenia. Therefore, the dorsal striatal dopamine level could be a promising treatment target for 237 schizophrenia (9, 31). In a recent clinical trial, a highly selective M4 positive allosteric modulator, i.e. responsible 238 for dopamine release in the dorsal striatum, has demonstrated a favourable safety profile in schizophrenia treatment 239 (32).

240 Previous studies have consistently found a surprisingly low genetic correlation between schizophrenia and 241 brain subcortical mean-based volume (22), which, as suggested by a recent finding (33), is likely because 242 subcortical mean-based volume and schizophrenia share plenty of common genetic variants but with heterogeneous 243 effects directions. In the present study, ReFS of multiple subcortical regions demonstrated significant genetic 244 correlations with schizophrenia, indicating that ReFS could help to capture a more homogenous genetic construct of 245 brain structure shared with schizophrenia (34). In terms of common genetic variants, we demonstrated that the same 246 SCZ risk alleles were simultaneously associated with increased positive-symptom Cog-ReFS (i.e. motor and 247 hallucination) and decreased negative-symptom Cog-ReFS (i.e. emotion, social and language) (Figure 3E), and 248 both groups of Cog-ReFS were also associated with schizophrenia diagnoses (Figure 2B). Hence, this latent 249 representation-based brain pattern (i.e. the ReFS) could also provide valuable insights into the genetic construction 250 of neural mechanisms underlying schizophrenia.

- 251
- 252 Acknowledgements
- **Author contributions**: Conceptualization: C.X., T.J.T., F.F.J.; Methodology: C.X., T.J.T.; Formal analysis: C.X.;
- 254 Writing: original draft: C.X., T.J.T.; Writing-review and editing: C.X., T.J.T, O.H., G.S., T.R.**Competing interests**:
- 255 The authors declare no competing interests. .

256

- 257 SUPPLEMENTARY MATERIALS
- 258 Materials and Methods
- 259 Figs. S1 to S14

260 Tables S1 to S20

261 ACKNOWLEDGMENTS

262 COBRE (The Center for Biomedical Research Excellence in Brain Function and Mental Illness) has published 263 structural and functional MRI data obtained from schizophrenia patients and normal subjects. MCICShare 264 comprised structural and resting-state functional MRI data, which was collected and shared by the Mind Research 265 Network and the University of New Mexico funded by a National Institute of Health Center of Biomedical 266 Research Excellence (COBRE) grant 1P20RR021938-01A2. Research using Human Connectome Project for Early 267 Psychosis (HCP-EP) data reported in this publication was supported by the National Institute of Mental Health of 268 the National Institutes of Health under Award Number U01MH109977. The HCP-EP 1.1 Release data used in this 269 report came from DOI: 10.15154/1522899. This work received support from the following sources: the National 270 Natural Science Foundation of China (T2122005 [to TJ], 82150710554 [to GS], KRH2306051 [CX] and 81801773 271 [to TJ]), China Postdoctoral Science Foundation (no. BX20230075 and 2023M740659 to CX). MOE Frontiers 272 Center for Brain Science [to CX], National Key R and D Program of China (2023ZY1068 [to TJ], 273 2019YFA0709501 [to TJ], 2021YFC2501402 [to TJ], 2019YFA0709502 [to JF], 2018YFC1312900 [to TJ] and 274 2018YFC1312904 [to JF]), the Shanghai Pujiang Project (18PJ1400900 [to TJ]), Guangdong Key Research and 275 Development Project (No. 2018B030335001 [to JF]), the European Union-funded FP6 Integrated Project IMAGEN 276 (Reinforcement-related behavior in normal brain function and psychopathology) (LSHM-CT- 2007-037286 [to 277 GS]), the Horizon 2020-funded ERC Advanced Grant' STRATIFY' (Brain network based stratification of 278 reinforcement-related disorders) (695313 [to GS]), the 111 Project (B18015 [to JF]), the key project of Shanghai 279 Science and Technology (16JC1420402 [to JF]), Shanghai Municipal Science and Technology Major Project (no. 280 2018SHZDZX01 [to JF]), ZJ Lab [to JF], Shanghai Center for Brain Science and Brain-Inspired Technology [to JF], 281 ERANID (Understanding the Interplay between Cultural, Biological and Subjective Factors in Drug Use Pathways) 282 (PR-ST-0416-10004, [to GS]), Human Brain Project (HBP SGA 2, 785907, and HBP SGA 3, 945539, [to GS]), the 283 Medical Research Council Grant' c-VEDA' (Consortium on Vulnerability to Externalising Disorders and Addictions) 284 (MR/N000390/1 [to GS]), the National Institute of Health (NIH) (R01DA049238, A decentralised macro and micro 285 gene-by-environment interaction analysis of substance use behavior and its brain biomarkers [to GS]), the National 286 Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation 287 Trust and King's College London, the Bundesministeriumfur Bildung und Forschung (BMBF grants 01GS08152; 288 01EV0711 [to GS]; the European Union and UKRI funded project environMENTAL (grants 101057429 [to GS]).

- 289 Forschungsnetz AERIAL 01EE1406A, 01EE1406B [to GS]), Forschungsnetz IMAC-Mind 01GL1745B [to GS]),
- the Deutsche Forschungsgemeinschaft (DFG grants SM 80/7-2, SFB 940, TRR 265, NE 1383/14-1, [to GS]).
- 291





293 Fig 1. The structural pattern-based representation feature analysis of striatum in schizophrenia. a. Concept 294 of pattern-based representation feature analysis. In regions with high spatial heterogeneity, univariate analysis 295 with mean/variance-based grey matter volume (GMV) failed to find significant group difference between 296 schizophrenia patients (SCZ) and healthy controls (HC). Spatial organization of functional references provide an 297 priori knowledge to decompose the spatial pattern of GMV into different latent representation dimensions, which 298 was termed as representational feature score (ReFS). The pattern-based ReFS help to detect the subtle spatial 299 distribution alternations of brain structure. **b**. The reliability, reproducebility and sensitivity analysis results of the 300 ReFS and mean-based volume. For each region, we used nine different neurotransmitter maps as pattern reference 301 to estimate the pattern-based ReFS, such as FDOP-ReFS, D1-ReFS etc. With the F-DOPA as an exmaple, the 302 reliability of brain ReFS was estimated as the spatial correlation between the F-DOPA maps from two public 303 available third-party datasets (Donders dataset and JuSpace). The reproducebility of brain ReFS and mean-based 304 volume was estimated as the intraclass correlation coefficient (ICC) with two repeated scanning datasets 305 (Myconnectome dataset, 1 participant was scanned 21 times; SIMON dataset, 1 participant was scanned 46 times). 306 The sensitivity of brain ReFS and mean-based volume was estimated as the accuracy in the brain fingerprint 307 analysis with a participant travelling dataset (SRPBS, 9 participants were scanned at 12 different sites). c. For each 308 subcortical region, there are complex nuanced group difference of spatial pattern between schizophrenia patients

309 and healthy controls. d. The group difference between schizophrenia and healthy control groups with univariate-

- based measurements of mean and variance and patter-based ReFS, which was estimated with nine group-level neurotransmitter maps. **e.** In subcortex, the group difference of schizophrenia with mean-based volume was
- 312 negatively associated with the group-level dopamine synthesis capacity (F-DOPA). **f**. In subcortex, the group
- difference of schizophrenia with F-DOPA-ReFS positively correlated with group-level dopamine synthesis capacity

314 (F-DOPA). g. After multiple corrections with Benjamin–Hochberg procedure, subcortical region with mean-based

- volume did not show significant group difference between schizophrenia patients, unaffected siblings, and healthy
- 316 controls; in contrast, the group difference with multiple PET-ReFS of striatum reached significant level, including
- 317 F-DOPA-ReFS of pPUI, D2-ReFS of pPUT, MU-ReFS of pGP. In subcortex, the group difference with PET-ReFS
- 318 exhibit significant higher level than with mean-based volume. The significance level was set as the corresponding
- 319 multiple correction in 16 regional mean-based volumes and 144 (16 regions * 9 neurotransmitters) pattern-based
- 320 subcortical PET-ReFS. The upper and lower bars represent the $Q3+1.5 \times IQR$ and $Q1-1.5 \times IQR$, respectively. The

321 upper and lower edges of a box represent the Q3 and Q1, and the central line represents the median. Outliers are

322 illustrated as bold dots. h. F-DOPA-ReFS of pPUT demonstrates a significant genetic risk gradient from healthy

323 controls, through unaffected siblings, to schizophrenia patients. **i.** Forest plot showing the effect sizes for the F-

324 DOPA-ReFS and GABA-ReFS of pPUT between schizophrenia patients and healthy controls. Meta-analysis

showed there was significantly higher F-DOPA-ReFS for pPUT (cohen's d=0.52 (95%CI = [0.41, 0.63]); P <

- 326 0.0001), whilst it was significantly lower for GABA-ReFS for o=pPUT in schizophrenia relative to controls
- 327 (cohen's d=--0.45 (95% CI= [-0.62 0.28]); P < 0.0001). Abbreviation: SCZ, schizophrenia patient; HC, healthy
- 328 control; ICC, intraclass correlation coefficient; F-DOP, Fluorodopa; FES, First episode schizophrenia patient;
- 329 Chronic: Chronic schizophrenia patient; Early Psy. Early psychosis patient. Sig. level, Significant level after

330 multiple correction; *P<0.05, **P<0.01, ***P<0.001. Q1, first quartile; Q3, third quartile; IQR, interquartile

331 range; SIMON, The Single Individual volunteer for Multiple Observations across Networks dataset; SRPBS,

332 Japanese Strategic Research Program for the Promotion of Brain Science. aHIP, anterior hippocampus; pHIP,

333 posterior hippocampus; IAMY, lateral amygdala; mAMY, medial amygdala; vpTHA, ventral posterior thalamus;

334 vaTHA, ventral anterior thalams; dpTHA, dorsal posterior thalamus; daTHA, dorsal anterior thalamus; coreNAC,

core nucleus accumbens; shellNAC, shell nucleus accumbens; aGP; pGP; aPUT; pPUT; aCAU; pCAU; FDOP;

- 336 GABA; D1, D2, SERT, MU, NAT; DAT;
- 337



338

339 Fig 2. Striatal ReFS with multidimensional latent cognitive factors in schizophrenia patients. a. Manhattan 340 plot illustrates significant group differences between schizophrenia and healthy controls in Cog-ReFS of subcortical 341 regions, particularly in pGP and pPUT. b. The group difference of Cog-ReFS in pPUT, pGP and daTHA. c. In these 342 regions, group differences of Cog-ReFS were notably modulated by neurotransmitters. d. High dimensional Cog-343 ReFS in subcortical regions could significantly predict the schizophrenic symptom subscales. e. The similarity 344 between predictive weights for different schizophrenia symptom subscales. f. The regional contribution of 345 subcortical Cog-ReFS in the predictive models of schizophrenia symptoms. g. The similarity between the summary 346 symptom's predictive contributors and case/control difference for all the Cog-ReFS in each subcortical region. 347



349

348

350 Fig 3. The shared genetic basis between brain Cog-ReFS and schizophrenia a. The genetic correlations were 351 calculated between brain ReFS (i.e. PET-ReFS and Cog-ReFS) of subcortical regions (GWAS using UKB) and the 352 summary statistics from a recent schizophrenia GWAS (Left). The counts of significant findings are shown on the 353 Right. b. In pPUT, ReFS with 125 latent cognitive factors and three neurotransmitters (D2, F-DOPA, DAT) had 354 positive significant genetic correlations with schizophrenia, and 138 latent cognitive factors and two 355 neurotransmitters (SERT1 and GABA) had negative genetic correlations. The volume of pPUT was not significantly associated with schizophrenia. c. Among the 279 single nucleotide polymorphisms (SNPs) from a 356 357 recent schizophrenia GWAS, 70% of SNPs (172) have significant correlations with the subcortical ReFS after false 358 discovery rate (FDR) correction and only 13% SNPs with subcortical mean-based volume. Four SNPs, i.e. 359 rs13107325, rs8084351, rs9398171, and rs7604885, predominated the SNP-brain ReFS associations (46%). d. The 360 SNP-brain ReFS associations of the four most representative SNPs showed different regional distributions. e. SNP 361 rs13107325 showed negative associations with the Cog-ReFS in pPUT for social emotion and language terms and 362 positive associations for motor and illusion terms. Rg, the genetic correlation; ReFS, representational feature score; 363 GWAS, genome-wide association study; UKB, UK biobank

364

365

366 367	Referei	nce
368		
369	1.	S. J. Kaar, S. Natesan, R. McCutcheon, O. D. Howes, Antipsychotics: Mechanisms underlying clinical response
370		and side-effects and novel treatment approaches based on pathophysiology. Neuropharmacology 172, 107704
371		(2020).
372	2.	M. C. Lobo, T. S. Whitehurst, S. J. Kaar, O. D. Howes, New and emerging treatments for schizophrenia: a
373		narrative review of their pharmacology, efficacy and side effect profile relative to established antipsychotics.
374		<i>Neurosci Biobehav Rev</i> 132 , 324-361 (2022).
375	3.	O. D. Howes, S. Kapur, The dopamine hypothesis of schizophrenia: version IIIthe final common pathway.
376		Schizophr Bull 35 , 549-562 (2009).
377	4.	S. Jauhar et al., A Test of the Transdiagnostic Dopamine Hypothesis of Psychosis Using Positron Emission
378		Tomographic Imaging in Bipolar Affective Disorder and Schizophrenia. JAMA Psychiatry 74, 1206-1213 (2017).
379	5.	O. D. Howes, C. Cummings, G. E. Chapman, E. Shatalina, Neuroimaging in schizophrenia: an overview of
380		findings and their implications for synaptic changes. <i>Neuropsychopharmacology</i> 48 , 151-167 (2023).
381	6.	T. G. van Erp et al., Subcortical brain volume abnormalities in 2028 individuals with schizophrenia and 2540
382		healthy controls via the ENIGMA consortium. <i>Mol Psychiatry</i> 21 , 547-553 (2016).
383	7.	S. V. Haijma et al., Brain volumes in schizophrenia: a meta-analysis in over 18 000 subjects. Schizophr Bull 39,
384		1129-1138 (2013).
385	8.	S. P. Brugger, O. D. Howes, Heterogeneity and Homogeneity of Regional Brain Structure in Schizophrenia: A
386		Meta-analysis. JAMA Psychiatry 74, 1104-1111 (2017).
387	9.	R. McCutcheon, K. Beck, S. Jauhar, O. D. Howes, Defining the Locus of Dopaminergic Dysfunction in
388		Schizophrenia: A Meta-analysis and Test of the Mesolimbic Hypothesis. <i>Schizophr Bull</i> 44 , 1301-1311 (2018).
389	10.	N. Chuhma, S. Mingote, A. Kalmbach, L. Yetnikoff, S. Rayport, Heterogeneity in Dopamine Neuron Synaptic
390		Actions Across the Striatum and Its Relevance for Schizophrenia. <i>Biol Psychiatry</i> 81, 43-51 (2017).
391	11.	K. M. Gothard, Multidimensional processing in the amygdala. Nat Rev Neurosci 21, 565-575 (2020).
392	12.	N. Kriegeskorte, R. A. Kievit, Representational geometry: integrating cognition, computation, and the brain.
393		<i>Trends Cogn Sci</i> 17 , 401-412 (2013).
394	13.	D. Alnaes et al., Brain Heterogeneity in Schizophrenia and Its Association With Polygenic Risk. JAMA
395		Psychiatry, (2019).
396	14.	A. Egerton et al., Presynaptic striatal dopamine dysfunction in people at ultra-high risk for psychosis: findings
397		in a second cohort. <i>Biol Psychiatry</i> 74, 106-112 (2013).
398	15.	S. Lariviere et al., BrainStat: A toolbox for brain-wide statistics and multimodal feature associations.
399		<i>Neuroimage</i> 266 , 119807 (2023).
400	16.	T. Yarkoni, R. A. Poldrack, T. E. Nichols, D. C. Van Essen, T. D. Wager, Large-scale automated synthesis of
401		human functional neuroimaging data. Nat Methods 8, 665-670 (2011).
402	17.	V. R. Karolis, M. Corbetta, M. Thiebaut de Schotten, The architecture of functional lateralisation and its
403		relationship to callosal connectivity in the human brain. Nat Commun 10, 1417 (2019).
404	18.	R. A. McCutcheon, T. Reis Marques, O. D. Howes, Schizophrenia-An Overview. JAMA Psychiatry, 1-10 (2019).
405	19.	T. Suto, M. Fukuda, M. Ito, T. Uehara, M. Mikuni, Multichannel near-infrared spectroscopy in depression and
406		schizophrenia: cognitive brain activation study. <i>Biological psychiatry</i> 55 , 501-511 (2004).
407	20.	D. A. Silbersweig et al., A functional neuroanatomy of hallucinations in schizophrenia. Nature 378, 176-179
408		(1995).
409	21.	B. F. McLean, J. K. Mattiske, R. P. Balzan, Association of the Jumping to Conclusions and Evidence Integration
410		Biases With Delusions in Psychosis: A Detailed Meta-analysis. Schizophr Bull 43, 344-354 (2017).
411	22.	B. Franke et al., Genetic influences on schizophrenia and subcortical brain volumes: large-scale proof of

412		concept. Nat Neurosci 19, 420-431 (2016).
413	23.	S. M. Smith et al., An expanded set of genome-wide association studies of brain imaging phenotypes in UK
414		Biobank. Nat Neurosci 24, 737-745 (2021).
415	24.	B. Zhao et al., Genome-wide association analysis of 19,629 individuals identifies variants influencing regional
416		brain volumes and refines their genetic co-architecture with cognitive and mental health traits. Nat Genet 51,
417		1637-1644 (2019).
418	25.	Z. Ning, Y. Pawitan, X. Shen, High-definition likelihood inference of genetic correlations across human
419		complex traits. Nat Genet 52, 859-864 (2020).
420	26.	V. Trubetskoy et al., Mapping genomic loci implicates genes and synaptic biology in schizophrenia. Nature,
421		(2022).
422	27.	X. Gao et al., Association between structural and functional brain alterations in drug-free patients with
423		schizophrenia: a multimodal meta-analysis. Journal of Psychiatry and Neuroscience 43, 131-142 (2018).
424	28.	S. S. Kuo, M. F. Pogue-Geile, Variation in fourteen brain structure volumes in schizophrenia: A comprehensive
425		meta-analysis of 246 studies. Neurosci Biobehav Rev 98, 85-94 (2019).
426	29.	R. A. McCutcheon, A. Abi-Dargham, O. D. Howes, Schizophrenia, Dopamine and the Striatum: From Biology
427		to Symptoms. Trends Neurosci 42, 205-220 (2019).
428	30.	B. J. Hunnicutt et al., A comprehensive excitatory input map of the striatum reveals novel functional
429		organization. elife 5, e19103 (2016).
430	31.	S. E. Yohn et al., Activation of the mGlu(1) metabotropic glutamate receptor has antipsychotic-like effects and
431		is required for efficacy of M(4) muscarinic receptor allosteric modulators. Mol Psychiatry 25, 2786-2799 (2020).
432	32.	J. H. Krystal et al., Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the
433		treatment of schizophrenia: a two-part, randomised, double-blind, placebo-controlled, phase 1b trial. Lancet
434		(London, England) 400, 2210-2220 (2022).
435	33.	W. Cheng et al., Shared genetic architecture between schizophrenia and subcortical brain volumes implicates
436		early neurodevelopmental processes and brain development in childhood. Mol Psychiatry, (2022).
437	34.	V. Anttila et al., Analysis of shared heritability in common disorders of the brain. Science 360, eaap8757 (2018).
438		